Yuflyma (Adalimumab)

Description

Yuflyma (adalimumab-aaty) is a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-a), a key mediator of inflammatory and immune responses. By blocking the interaction of TNF-a with its receptors, Yuflyma reduces inflammation and immune-mediated tissue damage. It is indicated for the treatment of multiple chronic autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, and uveitis, among others.

Directions

Yuflyma is administered by subcutaneous injection, with dosing regimens varying by condition and patient characteristics. For example:

• Rheumatoid arthritis (adults): 40 mg every other week

• Crohn’s disease (adults): 160 mg initially, 80 mg at week 2, then 40 mg every other week

• Plaque psoriasis: 80 mg initial dose, followed by 40 mg every other week starting one week later

Patients may self-administer Yuflyma after proper training. It is available in a prefilled autoinjector or prefilled syringe. The product should be stored refrigerated and brought to room temperature before use. Injection sites (thigh or abdomen) should be rotated with each dose.

Ingredients

Each 0.8 mL of Yuflyma contains:

• Adalimumab-aaty 40 mg

• L-histidine

• L-histidine hydrochloride monohydrate

• Sorbitol

• Polysorbate 20

• Water for injection

Yuflyma is citrate-free, latex-free, and preservative-free, which may reduce injection site discomfort.

Contraindications

Yuflyma is contraindicated in patients with:

• Known hypersensitivity to adalimumab or any component of the formulation

• Active tuberculosis, sepsis, or other severe infections

• Moderate to severe heart failure (in certain indications)

Cautions

Before starting Yuflyma, screen patients for latent or active tuberculosis and evaluate for hepatitis B. Monitor throughout therapy for infections, malignancy (especially lymphoma and skin cancers), demyelinating disorders, and cytopenias. Avoid concurrent use with other biologic immunomodulators. Live vaccines should not be given during treatment. Caution is advised in patients with a history of chronic or recurrent infections, or with underlying conditions that predispose them to infection.

Side Effects

Common side effects of Yuflyma include:

• Injection site reactions (pain, redness, swelling)

• Upper respiratory tract infections

• Headache

• Rash

• Nausea

• Sinusitis

Serious adverse effects may include:

• Serious infections (e.g., TB, bacterial sepsis)

• Malignancies (lymphoma, skin cancer)

• Hepatitis B reactivation

• Demyelinating disease (e.g., multiple sclerosis-like syndrome)

• Heart failure exacerbation

• Lupus-like syndrome

• Severe hypersensitivity reactions

Product Code : 14364